Why Is the Price of Mounjaro Going Up in the UK?

You opened your renewal email and the price had changed, here's why

Imagine logging in to reorder and finding a noticeably larger total. No explanation beyond a new figure on the page. That moment of confusion (or frustration) is something a lot of people on Mounjaro experienced in autumn 2025, and it is entirely understandable.

The straightforward answer is that Eli Lilly, the manufacturer of Mounjaro, revised its UK wholesale list price with effect from 1 September 2025. The increase was steep at the top of the dose range: the highest-strength pen, which previously carried a list price of roughly £122, rose to around £330. Lower strengths also increased, though the absolute jump was smaller. Because every private pharmacy or clinic in the UK buys stock at or close to that list price before adding their own margin, the change fed through into what patients pay almost immediately.

This wasn't a hidden change: Lilly communicated the revision to the supply chain in advance, and it was widely reported in the UK health press during August 2025. Still, for patients mid-treatment, the timing felt abrupt. If you want a fuller breakdown of how individual providers have responded, our dedicated page on the Eli Lilly Mounjaro price increase covers the detail.

Is Mounjaro going up again, or has the price stabilised?

As of summer 2026, no further list-price increase has been announced by Eli Lilly in the UK. The September 2025 revision was a one-time structural change, not the start of regular quarterly hikes. That said, private providers can adjust their own retail prices at any time, so what you pay at a particular clinic or pharmacy may shift independently of the manufacturer.

Several factors influence whether a provider's price moves. Stock availability, operational costs, and how a provider bundles ancillary services (consultation fees, prescriptions, aftercare, delivery) all affect the final figure. Some providers absorbed part of the manufacturer increase; others passed it through in full. When you're comparing prices, it is worth checking exactly what the quoted number includes, because headline prices that exclude a consultation fee or next-day delivery can look cheaper than they are.

If you're trying to understand why your progress has slowed at your current dose, that's a separate clinical question worth discussing with your prescriber, titrating to a higher dose to improve results would now come at a higher monthly cost, which is another reason the price structure matters practically.

What the price rise means if you're thinking about starting Mounjaro

The September 2025 increase changed the economic picture for anyone weighing up whether to start treatment. At the starting 2.5mg dose the monthly outlay is more manageable, but the licensed titration schedule typically progresses to higher doses over several months, and the cost curve rises with it. Understanding that trajectory upfront helps you plan.

It's also worth knowing that Mounjaro's clinical results (around 20–21% average body-weight reduction at the highest dose over 72 weeks in the SURMOUNT-1 trial, published in the New England Journal of Medicine) reflect maintenance doses, not the starter pen. The early weeks of treatment are about tolerability, not maximum effect. More background on how Mounjaro produces weight loss may help you set realistic expectations before committing financially.

The NICE appraisal of tirzepatide (NICE TA1026) recommends it for eligible NHS patients, but NHS access remains phased and limited in 2026. Private treatment through a regulated pharmacy remains the route for most people who don't meet current NHS criteria or prefer not to wait. When you compare providers, a lower price that excludes clinical review, aftercare, or a legitimate prescribing process is not a straightforward saving.

How to think about cost without making it the only factor

Price is a reasonable thing to research. Mounjaro is a meaningful monthly expense, and the 2025 increase made it more so. At the same time, for a prescription medicine that requires clinical oversight throughout treatment, the cost of safe, supervised supply is part of what you're paying for, and the cheapest listing answers the wrong question if the prescribing or supply chain behind it isn't verifiable. If you've previously stopped treatment and are now reconsidering, our guide to going back on Mounjaro after a break walks through what to expect clinically and financially before you restart.

Every pharmacy dispensing Mounjaro in the UK must be registered with the General Pharmaceutical Council; you can check any provider at the GPhC pharmacy register before placing an order. Medicines sourced through unverified online sellers, particularly those advertising prices well below the current market range, carry a real risk of being counterfeit, the MHRA has seized large quantities of fake weight-loss pens and issued repeated public warnings about this.

At nume, we include the prescriber consultation, the prescription, and free next-working-day DPD delivery in one transparent price, no subscription, no auto-renewal, no extras added at checkout. Our treatment page shows current pricing clearly, and if you're weighing up whether restarting makes sense for you, our page on going back on Mounjaro covers the key considerations. If you'd like to check whether you're eligible, a free consultation with one of our prescribers is a good place to start, and reading what patients say about their experience on our Mounjaro Trustpilot reviews page may help you feel confident in that decision. Our clinical team reviews every consultation personally.